5-Amino-1MQ

5-Amino-1MQ is a small molecule studied for its potential to help the body shrink fat cells and raise NAD+ levels without cutting appetite.

It works by blocking an enzyme called NNMT (nicotinamide N-methyltransferase), which, when elevated in fat tissue, depletes vitamin B3 necessary for NAD+ production. By inhibiting NNMT, it preserves B3, increases NAD+, and promotes fat cells to function more like lean tissue. [Source: Peptide Dosing Protocols]

5-Amino-1MQ, or 5-amino-1-methylquinolinium, is a small molecule that functions primarily as an NNMT (nicotinamide N-methyltransferase) inhibitor. NNMT is an enzyme that, when overactive in fat tissue, depletes a form of vitamin B3 necessary for the synthesis of NAD+ (nicotinamide adenine dinucleotide), which is crucial for cellular energy metabolism. By inhibiting NNMT, 5-Amino-1MQ helps to conserve vitamin B3, thereby increasing NAD+ levels within cells. This mechanism allows fat cells to behave more like lean tissue, promoting fat cell shrinkage without suppressing appetite.

The research surrounding 5-Amino-1MQ has primarily been conducted in preclinical settings, including cell culture and rodent studies. For instance, a study by Neelakantan et al. (Biochemical Pharmacology, 2018) demonstrated that 5-Amino-1MQ at a concentration of 30 µM significantly reduced 1-MNA levels in mouse adipocytes, confirming its role as an NNMT inhibitor. Further rodent studies have shown that subcutaneous administration of 5-Amino-1MQ can lead to reductions in body weight and white adipose tissue without affecting food intake or lean mass. Notably, Babula et al. (2024) reported dose-dependent reductions in body weight and fat mass over a 28-day treatment period, alongside improvements in fatty liver markers.

The mechanism of action is particularly appealing to researchers because it allows for fat loss and increased NAD+ levels without the common side effect of appetite suppression. This is a significant advantage over other weight loss interventions that often lead to reduced food intake. The typical dosing regimen in research contexts ranges from 50 to 150 mg per day, taken orally, with cycles lasting between 8 to 12 weeks followed by a break of 4 to 6 weeks. However, it is important to note that as of June 2026, 5-Amino-1MQ has not been FDA-approved, and there are no published human clinical trials to validate its safety and efficacy in humans. [Source: Peptide Dosing Protocols]

Provider notes: [PDP compound] 5-amino-1mq